Evolus, Inc. commercializes cash-pay medical aesthetic products for the global performance beauty market. Its portfolio centers on Jeuveau® (prabotulinumtoxinA-xvfs), known as Nuceiva® outside the United States, and injectable hyaluronic acid gel collections marketed under the Evolysse® and Estyme® brands.
Recurring Evolus news includes quarterly financial results, revenue outlooks, product and market expansion for injectable aesthetics, CE Mark certification for HA gel collections, national-account and customer engagement updates, healthcare conference participation, and equity compensation grants under Nasdaq inducement rules. Company updates also discuss operations across the United States, Canada, Europe, and Australia.
Evolus (NASDAQ: EOLS) reported Q2 2025 financial results with global net revenue of $69.4 million, up 4% year-over-year despite market headwinds. The growth was driven by the successful launch of Evolysse™, which contributed $9.7 million in revenue, and strong international performance.
The company reported a GAAP operating loss of $10.2 million and ended the quarter with $61.7 million in cash. Evolus revised its 2025 revenue guidance to $295-305 million and expects to achieve profitability in Q4 2025. The company maintains its 2028 revenue target of $700 million with projected non-GAAP operating margins of 20%.
Key operational metrics include over 16,500 total purchasing accounts, a 70% reorder rate, and 1.2 million members in the Evolus Rewards™ program. The company announced cost optimization measures expected to yield $25 million in non-GAAP operating expense savings for 2025.
Evolus (NASDAQ: EOLS) announced the publication of a landmark independent study in JAMA Dermatology comparing four FDA-approved neurotoxins for treating glabellar lines. The double-blind study of 143 female participants aged 30-65 demonstrated Jeuveau®'s superior performance against competitors Botox®, Dysport®, and Xeomin®.
Key findings showed that Jeuveau® achieved the highest peak effect with a 93% median strain reduction at Day 30, demonstrated fast onset of action at Day 3, and maintained significant duration at Day 180, outperforming Botox® at this timepoint. The study validates Jeuveau®'s market success, which has achieved over 14% U.S. market share and penetrated more than 50% of aesthetic clinics, becoming the fastest-growing neurotoxin for four consecutive years.
Evolus (NASDAQ: EOLS), a performance beauty company focused on aesthetic consumer brands, has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after market close.
Management will host a conference call and webcast at 4:30 p.m. ET the same day, including a Q&A session. Participants can join via phone at (877) 407-6184 (U.S.) or (201) 389-0877 (international), or through the webcast on Evolus's Investor Relations webpage.
Evolus (NASDAQ: EOLS), a performance beauty company, has granted 12,385 restricted stock units (RSUs) to 6 newly hired non-executive employees under its 2023 Inducement Incentive Plan. The RSUs were granted on July 7, 2025, as approved by the company's compensation committee.
The RSUs will vest over a four-year period, with 25% vesting annually on each anniversary of the grant date. Continuous employment is required for vesting, and the awards are subject to the terms and conditions of both the Incentive Plan and respective RSU agreements.
Evolus (NASDAQ: EOLS) has announced its expansion into the French market through a partnership with Symatese for the distribution of Nuceiva® (botulinum toxin type A). The product is approved by the European Commission for treating moderate to severe glabellar lines in adults under 65 years.
Nuceiva®, marketed as Jeuveau® in the United States, has been the fastest-growing neurotoxin in the U.S. for four consecutive years. The product's safety and efficacy were validated through the TRANSPARENCY clinical program, which included three Phase III trials and two long-term safety studies, featuring the largest head-to-head aesthetic pivotal study versus Botox® to date.
The partnership with Symatese, a French company specializing in regenerative medical solutions, will enable direct order and delivery to French medical aesthetics healthcare professionals.
Evolus (NASDAQ: EOLS) has granted equity incentives to 16 newly hired non-executive employees in May 2025. The compensation package includes 12,706 non-qualified stock options with an exercise price of $9.98 per share and 40,576 restricted stock units (RSUs). The stock options have a 10-year term and vest over 4 years, with 25% vesting annually. Similarly, the RSUs vest 25% each year. These awards were approved under the Evolus 2023 Inducement Incentive Plan, with a grant date of May 12, 2025, and vesting commencement date of May 7, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).